|Tested species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Storage buffer||PBS, pH 7.2, with 0.1% gelatin, 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, store in dark, DO NOT FREEZE!|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||5 µL (0.25 µg)/test|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Description: The 6H6 monoclonal antibody reacts with human CD123, the alpha chain of the IL-3 receptor. This 60-70 kDa transmembrane protein binds to IL-3 with low affinity by itself, and when associated with CD131 (common beta chain) binds IL-3 with high affinity. CD123 is expressed by myeloid precursors, macrophages, dendritic cells, mast cells, basophils, and megakaryocytes.
Applications Reported: This 6H6 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This 6H6 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser
IL-3Ra (Interleukin-3 receptor subunit alpha) belongs to the type I cytokine receptor family and is a heterodimer with a unique alpha chain paired with the common beta (beta c or CDw131) subunit. It is responsible for the transmission of signal of Interleukin-3. IL-3Ra and IL-3Rb chain heterodimerization is induced by Interleukin-3, which is required for receptor activation but not high affinity binding. It is also reported that IL-3Ra subunits are overexpressed on acute myeloid leukemia (AML) blasts compared with normal hematopoietic cells and are thus potential targets for novel therapeutic agents.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
||CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer.||Assaf C,Gellrich S,Whittaker S,Robson A,Cerroni L,Massone C,Kerl H,Rose C,Chott A,Chimenti S,Hallermann C,Petrella T,Wechsler J,Bagot M,Hummel M,Bullani-Kerl K,Bekkenk MW,Kempf W,Meijer CJ,Willemze R,Sterry W||Journal of clinical pathology (60:981)||2007|
|Not Applicable||Not Cited||CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer.||Assaf C,Gellrich S,Whittaker S,Robson A,Cerroni L,Massone C,Kerl H,Rose C,Chott A,Chimenti S,Hallermann C,Petrella T,Wechsler J,Bagot M,Hummel M,Bullani-Kerl K,Bekkenk MW,Kempf W,Meijer CJ,Willemze R,Sterry W||Journal of clinical pathology (60:981)||2007|
|Not Applicable||Not Cited||Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI.||Xu W,He B,Chiu A,Chadburn A,Shan M,Buldys M,Ding A,Knowles DM,Santini PA,Cerutti A||Nature immunology (8:294)||2007|
|Not Applicable||Not Cited||Local activation of the innate immune system in Buruli ulcer lesions.||Peduzzi E,Groeper C,Schütte D,Zajac P,Rondini S,Mensah-Quainoo E,Spagnoli GC,Pluschke G,Daubenberger CA||The Journal of investigative dermatology (127:638)||2007|
|Not Applicable||Not Cited||Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms.||Jaye DL,Geigerman CM,Herling M,Eastburn K,Waller EK,Jones D||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (19:1555)||2006|